Abstract The urokinase receptor (uPAR) plays a critical role in breast cancer (BC) progression and metastases and is a validated target for novel therapies. The current study investigates the effects of MV-uPA, an oncolytic measles virus fully retargeted against uPAR in syngeneic and xenograft BC metastases models. In vitro replication and cytotoxicity of MVs retargeted against human (MV-h-uPA) or mouse (MV-m-uPA) uPAR were assessed in human and murine cancer and non-cancer mammary epithelial cells. The in vivo effects of species-specific uPAR retargeted MVs were assessed in syngeneic and xenograft models of experimental metastases, established by intravenous administration of luciferase expressing 4T1 or MDA-MD-231 cells. Metastases progression was assessed by in vivo bioluminescence imaging. Tumor targeting was evaluated by qRT-PCR of MV-N, rescue of viable viral particles, and immunostaining of MV particles in lungs from tumor bearing mice. In vitro, MV-h-uPA and MV-m-uPA selectively infected, replicated, and induced cytotoxicity in cancer compared to non-cancer cells in a species-specific manner. In vivo, MV-m-uPA delayed 4T1 lung metastases progression and prolonged survival. These effects were associated with identification of viable viral particles, viral RNA, and detection of MV-N by immunostaining from lung tissues in treated mice. In the human MDA-MB-231 metastases model, intravenous administration of MV-huPA markedly inhibited metastases progression and significantly improved survival, compared to controls. No significant treatment-related toxicity was observed in treated mice. The above preclinical findings strongly suggest that uPAR retargeted measles virotherapy is a novel and feasible systemic therapy strategy against metastatic breast cancer.
Introduction
According to the American Cancer Society, approximately 232, 670 new cases of invasive breast cancer and 40,000 breast cancer deaths are expected to occur among US women in 2014 [1] . Even though significant progress has been made in the management of early and locally advanced breast cancer, metastatic breast cancer is an incurable disease, associated with a poor prognosis [2] .
The plasminogen activator system plays a critical role in breast cancer progression and metastases [3] . Both urokinase and its inhibitor plasminogen activator inhibitor-1 (PAI-1) are clinically validated prognostic and predictive biomarkers for disease free survival and overall survival in breast cancer patients [4] [5] [6] [7] . The urokinase receptor (uPAR), a glycosylphosphoinositol (GPI) anchored cell surface receptor, binds uPA with high affinity and is critical for protease-mediated cancer cell invasion, as well as protease independent signaling pathways involved with the metastatic process, such as proliferation, migration, and epithelial to mesenchymal transition (EMT) [8] [9] [10] . It is overexpressed in a variety of human and murine cancers, compared to non-cancer tissues, and its presence has been associated with high metastatic potential and poor prognosis [11] [12] [13] [14] [15] [16] [17] .
The oncolytic virotherapy field has significantly expanded in the last decade, and recently, several novel viral vectors have reached late phase clinical evaluation [18] . Among the novel oncolytic viruses under development, the Edmonston vaccine strain of measles virus (MVEdm) is a promising one, whose in vitro and in vivo safety and efficacy are well established [19, 20] . Recombinant, non-targeted oncolytic MVs are currently being evaluated in ovarian cancer, brain tumors, multiple myeloma and mesothelioma [18, 21, 22] , with promising preliminary reports of clinical antitumor efficacy [23] . Redirecting viral tropism to tumor specific targets is an active area of research in the field of oncolytic viruses, which has the potential to improve safety and delivery of viral vectors to sites of distant metastases.
Based on the above, our group has successfully engineered and rescued an oncolytic measles virus fully retargeted against the urokinase receptor (MV-uPA) [24] . Species-specific MV-uPA vectors were engineered by displaying the aminoterminal fragment (ATF) of either human (MV-h-uPA) or mouse (MV-m-uPA) urokinase in the C-terminus of a CD46 and SLAM ''blind'' MV-H glycoprotein (H AALS ) [24] . Recombinant oncolytic MVs retargeted against that human or mouse uPAR induces antitumor effects in primary (mammary fat pad) breast cancer models in vivo [24] . In this report, the in vivo effects of uPAR retargeted oncolytic measles viruses in human and murine experimental breast cancer metastases models were investigated.
Results
In vitro tumor selectivity and species specificity of uPAR-dependent MV-h-uPA and MV-m-uPA
The engineering and rescue of fully retargeted oncolytic measles viruses against human (MV-h-uPA) or murine (MV-m-uPA) uPAR were reported by our group [24] . To determine the in vitro tumor selectivity and species specificity of the above viruses in breast cancer, human and murine mammary cancer (known to express uPAR [24] [25] [26] , as well as normal (human and murine) mammary epithelial cells were infected with MV-GFP (non-targeted measles virus), MV-h-uPA, and MV-m-uPA. The human MDA-MB-231, MCF-7, and MDA-MB-436 breast cancer cell lines were sensitive to both MV-GFP and MV-h-uPA infection, as demonstrated by strong virally induced GFP expression and syncytia formation, but not to the murine uPAR retargeted virus (Fig. 1a, b, c) . Infection of non-cancerous human mammary epithelial cells (HMEC) was less prominent than cancer cells. However, the permissivity of HMEC was markedly less for MV-h-uPA compared to MV-GFP (Fig. 1d) . Murine 4T1 mammary cancer cells were only permissive to the species specific MV-m-uPA and not to the human retargeted viruses (Fig. 1e) . Neither virus was able to infect non-cancer murine mammary epithelial cells (NMuMG, Fig. 1f) . The above findings clearly confirm species and tumor cell specificity of the human and murine uPAR retargeted MVs against breast cancer in vitro.
Next, to determine whether MV-uPA preferentially replicates in breast cancer cell lines compared to normal breast epithelial cells, MDA-MB-231, MCF-7, MDA-MB-436, and 4T1 (cancer cells), as well as HMEC and normal mammary epithelial cells (NMuMG), were infected with the human or murine uPAR retargeted virus. Titers of virus were determined at 24, 48, and 72 h by the one-step growth curve. As shown in Fig. 2a-c , MV-h-uPA successfully replicated in human breast cancer cells (viral titers -TCID 50 -at 72 h: MDA-MB-231 = 1.5 9 10 6 ; MCF-7 = 4 9 10 6 ; MDA-MB-436: 6.9 9 10 5 ), but significantly less in HMEC (1.2 9 10 3 and 2.4 9 10 1 TCID 50 at 48 and 72 h, respectively). MV-m-uPA successfully replicated in murine cancer cells 4T1 (1.1 9 10 4 TCID 50 at 72 h) but not in mouse mammary epithelial cells (NMuMG) (Fig. 2e, f) .
In vitro cytotoxicity
The cytopathic effects of MV-h-uPA and MV-m-uPA were determined at different time points after infection, by trypan blue exclusion. MV-h-uPA induced significant (p \ 0.0001) cytotoxicity at 48 and 72 h after infection in all of human breast cancer cells (Fig. 3a, b, c) . MV-m-uPA, on the other hand, induced significant cytotoxicity in the murine tumorigenic cell lines 4T1 at 72 h (p = 0.0292; 3. F). MV-h-uPA and MV-m-uPA caused minimal cytopathic effects against normal human (HMEC; Fig. 3d ) or murine (NMuMG) mammary epithelial cells (Fig. 3e) .
In vivo effects of MV-m-uPA on syngeneic mammary cancer metastases
The highly aggressive 4T1 experimental lung metastases model was established as described in methods. At day 7 after tumor cell injection (when significant lung bioluminescence was detected), mice were treated with three IV injections (every other day) of vehicle (PBS), or MV-muPA. Metastases progression was measured by in vivo luciferase imaging, as shown in Fig. 4a , c. Treatment with MV-m-uPA was associated with significant delay in tumor metastases (p = 0.0303) as well as a modest, but statistically significant prolongation of survival (p = 0.0149) compared to control mice (Fig. 4b) . In vivo anti-metastatic effects in a xenograft model of experimental metastases
To further extend the above findings in a human model of breast cancer metastasis, MDA-MB 231-luc2 cells were intravenously administered to female NOD/SCID mice. Three weeks after tumor cell administration, mice were treated with three IV injections of vehicle or the human uPAR retargeted MV (MV-h-uPA). Metastases progression was measured weekly in vivo luciferase imaging of lung metastases for 6 weeks after treatment. As shown in Fig. 5a -c, treatment with MV-h-uPA was associated with significant delay in tumor metastases (p = 0.0093) compared to control mice. This was translated into significant prolongation of survival in mice treated with MV-h-uPA (p = 0.0057), compared to controls (Fig. 5d) .
Determination of viral RNA and viable virus from lungs of treated mice Additional tumor-bearing mice were treated with MV-huPA intravenously at days 30 and 60 after tumor cell inoculation, and lungs were harvested at day 3 after treatment. Viral RNA was detected in all treated mice at both time points (Fig. 6e) , similar to our findings in the syngeneic model. Virus recovery assays were performed from lungs at day 3 after MV-h-uPA treatment. Infectious viral particles were rescued from 1 of 3 lungs at each time point (Fig. 6f) , while no virus was rescued from the control group (not shown).
Discussion
The urokinase receptor plays a critical role in tumor progression and metastases in breast and other cancers [10, 13, [27] [28] [29] [30] [31] , and represents an ideal target for novel biotherapies. As this receptor is predominantly expressed in cancer compared to non-cancer tissues, uPAR-directed agents, like anti-uPAR antibodies or uPAR targeted nanoparticles, have the potential to successfully target primary tumors and metastases in vivo, without affecting non-tumor-bearing organs [27, 32] . Other uPAR-directed strategies that have demonstrated in vivo antitumor efficacy include uPAR antisense oligonucleotides [33] and radiolabeled anti-uPAR antibodies [34] . The Edmonston strain of measles virus is a promising oncolytic platform with an established track record of safety and preclinical antitumor activity. The clinical antitumor potential of this viral vector was recently shown in studies by Russell et al. [23] , and Galanis et al. [22] , who reported antitumor effects in patients with multiple myeloma and ovarian cancer, after intravenous and intraperitoneal administration of MV-NIS, an oncolytic MV expressing the sodium iodide symporter, respectively.
Redirecting the virus tropism has the potential to improve tumor selectivity, especially to sites of distant metastases. We have previously demonstrated that MVuPA, a fully retargeted oncolytic measles against the urokinase receptor is safe and induces antitumor effects against primary (mammary fat pad) human breast cancer [24] . Intravenous administration of MV-m-uPA, retargeted to murine uPAR, was associated with tumor selective replication and lack of organ toxicity in a syngeneic, immunocompetent model of primary mammary cancer [35] .
The current report demonstrates for the first time the promising anti-metastatic activity of MV-m-uPA and MVh-uPA. In vitro, our studies clearly showed that uPARmediated targeting preferentially affects breast/mammary cancer and not normal mammary epithelial cells in a species specific manner. We observed that MV-h-uPA replication in human breast cancer cell lines was more efficient than that in murine 4T1 cells, as reflected by higher viral titers at 48 and 72 h, and more potent cytotoxic effects in human, compared to murine breast cancer than in murine 4T1 cells.
The 4T1 experimental metastases model is highly aggressive, where mice develop lung metastases rapidly (within 7 days), and the majority of mice die within the first 3 weeks. Intravenous administration of MV-m-uPA significantly delayed the rapid progression of lung metastases (Fig. 4a) , and even with only three treatments, given in the first week of therapy, survival was improved. We clearly showed the evidence of viral targeting of metastases, as well as the presence of both viable, replicating viral vectors, and viral RNA in lungs from treated, tumorbearing mice (Figs. 4d, e, f, g ). These results indicate successful targeting as well as the biological and antitumor effects of this agent in this highly aggressive model. Importantly, these findings were validated in the experimental human MDA-MB-231 metastases model. The metastases delaying effects were markedly reduced in the treated animals, and survival was significantly prolonged. Similar to the syngeneic model, viable virus and viral RNA were found in the lungs of treated animals. As MV-h-uPA only targets human (and not murine) uPAR, the presence of viral particles and RNA 3 days after virus administration demonstrates the effective in vivo viral targeting of human tumor cells.
While marked anti-metastatic effects and survival prolongation were observed in the xenograft model, no long-term survival was observed in the 4T1 metastases model. There are several reasons that may explain these findings, including the highly aggressive nature of the 4T1 model (development of large nodules early after tumor cell inoculation), limited number of treatments, and the less permissive nature of 4T1 cells found in vitro, compared to human breast cancer cell lines. In addition, the development of antiviral immunity in mice with an intact immune system likely plays an important role in reducing viral propagation over time. The results obtained from our syngeneic model prove the concept that uPAR targeting of metastatic lesions in immunocompetent models of cancer metastases is safe and feasible, and will lead to future studies aimed at further characterizing the best schedule and timing of treatment with MV-m-uPA. As the majority of previously reported targeted oncolytic MVs are directed against human, and not murine targets [36] [37] [38] [39] [40] , MV-m-uPA offers the advantage of testing safety and antitumor effects in syngeneic, immunocompetent animals, without the need to use transgenic mice or modified mouse cell line models. An important, but unexplored area of research in oncolytic virotherapy, which can be tested with our agents in immunocompetent and immunodeficient models, is the evaluation of the role of this fully retargeted viral agent in the prevention of micrometastases, either in experimental or spontaneous metastases. This could open a novel strategy for future studies of retargeted oncolytic viruses in general, and uPAR targeted viral agents in particular, in the postoperative setting in highrisk patients with breast and other malignancies.
In summary, our studies demonstrate successful uPARmediated targeting and delay in metastases progression in vivo, in both immunocompetent and immunodeficient mammary cancer metastasis models. Our observations validate at a preclinical level the feasibility and activity of MV-uPA in the metastatic setting after systemic administration. Further characterization of this strategy in the prevention of metastases after surgery and combination therapies with agents to improve the efficacy and replication of the viral vector in vivo is underway.
Materials and methods

Virus preparation and cell culture
Constructions of MV-m-uPA and MV-h-uPA, virus rescue, propagation, and titration were performed as previously reported [24, 36] . 4T1 cells (murine mammary carcinoma), MDA-MB-231 cells (human breast cancer), MCF-7 cells (human breast cancer), and MDA-MB-436 cells (human breast cancer) were purchased from the American Type Culture Collection (ATCC, Manassas, VA). 4T1-luc2 cells stably expressing highly efficient luciferase were from PerkinElmer (Santa Clara, CA). Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10 % fetal bovine serum (FBS), penicillin and streptomycin at 37°C and 5 % CO 2 . HMEC cells (human mammary epithelial cells) were purchased from Lonza (Walkersville, MD) and maintained in MEGM according to manufacture's instruction at 37°C and 5 % CO 2 . NMuMG (murine mammary epithelial cells) were purchased from the ATCC and maintained in DMEM containing 10 % FBS, penicillin and streptomycin at 37°C and 5 % CO 2 . Vero-aHis cells [36] were grown in DMEM containing 10 % FBS at 37°C and 5 % CO 2 .
In vitro infection 10 4 of each cell line in a 24-well plate were incubated with each MV at an MOI of 1 in Opti-MEM for 2 h at 37°C. At the end of the incubation period, free viruses were removed and cells were maintained in the appropriate medium. At 48 h after infection, cells were photographed under fluorescence microscopy (Nikon, Melville, NY).
Assessment of in vitro cytopathic effects
Cells were plated in six-well plates at a density of 10 5 per well. Twenty-four hours after seeding, the cells were infected at MOI = 1 in 1 mL of Opti-MEM for 2 h at 37°C. At the end of the incubation period, the virus was removed, and cells were maintained in their standard medium. At 48 h, 72 h after infection, the number of viable cells (determined by trypan blue exclusion) in each well was counted using Vi-Cell cell viability analyzer (Beckman Coulter, Fullerton, CA).
In vitro replication
Each cell line (in duplicate) was infected with measles virus at an MOI of 3 and incubating at 37°C, 5 % CO 2 for 2 h, after which the virus was removed, and cells were maintained in 5 % FBS of DMEM at 37°C. Virus titers were obtained by titration on Vero-aHis cells and expressed as 50 % tissue culture infectious dose (TCID50)/mL at the specified time points.
Animal studies Animal studies were approved by the Institutional Animal Care and Use Committee of University of Miami.
Characterization of MV-m-uPA's in vivo oncolytic effects in immunocompetent cancer murine models The lung metastases model was established by tail vein injection of 2 9 10 5 4T1-Luc2 cells (Caliper) in 100 lL of PBS in female BALB/C mice. At day 7 after tumor cell injection, mice were (n = 10/group) treated with three IV injections (every other day) of vehicle (PBS), or MV-m-uPA (1 9 10 6 TCID 50 in 100 lL PBS). Endpoints of the study were tumor progression and survival. Metastases progression was measured by in vivo luciferase imaging.
Characterization of MV-h-uPA's in vivo oncolytic effects in xenograft metastases model Female NOD/SCID mice (7-8 weeks) were received 2 9 10 5 MDA-MB231-luc2 cells (Caliper) in 100 lL of PBS via tail vein. 3 weeks after tumor cell injection, mice were (n = 8/group) treated with three IV injections (every other day) of either vehicle (PBS), or MV-h-uPA (1 9 10 6 TCID 50 in 100 lL PBS). Endpoints of the study were tumor progression and survival. Metastases progression was measured by in vivo luciferase imaging at days 0, 7, 14, 21, and 28 after treatment. In vivo luciferase imaging was evaluated as follows: mice were intraperitoneally injected with D-luciferin (Caliper) at a dose of 150 mg/kg per mouse and anesthetized. Bioluminescence images were then acquired using Xenogen IVIS imaging system. Bioluminescence signal was quantified as photon flux (photons/s/cm2) in defined regions of interest using Living Image software (Xenogen).
Immunohistochemistry and immunofluorescence studies
Tumor-bearing mice (n = 3) were treated with two intravenous injections of 1.5 9 10 6 TCID 50 of MV-muPA at days 10 and 17 after tumor cell inoculation. Mice were sacrificed and tumors resected after 72 h of the last injection (in each time point), for immunohistochemistry and immunofluorescence studies to detect MV-N protein.
Tissue samples were collected and frozen, and cryostat sections were fixed in cold acetone for 10 min, and endogenous peroxidase activity was quenched with 0.3 % H 2 O 2 for 10 min. The slides were washed in PBS and incubated with biotinylated mouse anti-MV-nucleoprotein antibody (Chemicon International, Temecula, CA) for 30 min at 37°C. After washing in PBS, the slides were developed with VECTASTAIN ABC horseradish peroxidase (HRP) kit (Vector Laboratories) and 3,3,9-diaminobenzidine (DAB) HRP substrate (Vector Laboratories) according to the manufacturer's instructions. For anti-MV immunofluorescence staining, cryostat sections were fixed in cold acetone for 10 min. The slides were washed in PBS and incubated with anti-MVnucleoprotein-FITC antibody (Chemicon International) for 30 min at 37°C.
Virus recovery
Tissues were weighed and homogenized in three volumes (w/v) of Opti-MEM utilizing mechanical crushing and a single freeze thaw cycle. The supernatant was clarified by centrifugation, and ten-fold serial dilutions of samples were prepared in Opti-MEM. Aliquots (50 lL) of each dilution were placed in 96-well plates containing Vero-his cells, and TCID 50 titrations were performed. TCID 50 calculations were normalized per gram of tissue.
Viral RNA quantification
Total RNA was extracted from frozen specimens using the RNeasy tissue mini kit (Qiagen, Valencia, CA) following the manufacturer's recommendations. qRT-PCR for MV-N mRNA was performed as previously reported [41] .
Statistical analysis
In vitro data are presented as means ± standard deviations. Results from in vivo studies are shown as mean ± standard error of the mean. All in vitro experiments were performed in triplicate unless otherwise specified. Statistical analysis among groups was performed by analysis of variance. Subgroup comparisons were made after the overall analyses using the Student t test, Tukey-Kramer, Fisher's, or Wilcoxon rank-sum test, as appropriate. Overall survival was analyzed by the Kaplan-Meier method, and differences were analyzed by the log-rank test. Statistical significance was set at p = 0.05, with adjustments for multiple comparisons as appropriate. All statistical tests were two-sided.
